Rocket Historical Income Statement
| RCKT Stock | USD 14.20 0.09 0.64% |
Historical analysis of Rocket Pharmaceuticals income statement accounts such as Research Development of 195.7 M, Total Operating Expenses of 272.6 M, Total Other Income Expense Net of 14.8 M or Total Revenue of 0.0 can show how well Rocket Pharmaceuticals performed in making a profits. Evaluating Rocket Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Rocket Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Rocket Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rocket Pharmaceuticals is a good buy for the upcoming year.
Rocket |
About Rocket Income Statement Analysis
Rocket Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Rocket Pharmaceuticals shareholders. The income statement also shows Rocket investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Rocket Pharmaceuticals Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Rocket Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Rocket Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.At this time, Rocket Pharmaceuticals' Non Operating Income Net Other is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 12.9 M in 2024, despite the fact that EBITDA is likely to grow to (224.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 5.9M | 1.9M | 1.9M | 3.3M | Depreciation And Amortization | 5.4M | 6.3M | 7.1M | 7.5M |
Rocket Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Rocket Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rocket Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.1M | 1.1M | 5.4M | 6.3M | 7.1M | 7.5M | |
| Interest Expense | 4.8M | 7.5M | 5.9M | 1.9M | 1.9M | 3.3M | |
| Selling General Administrative | 17.5M | 27.9M | 41.8M | 58.8M | 73.3M | 77.0M | |
| Other Operating Expenses | 75.9M | 134.3M | 166.2M | 223.8M | 259.7M | 272.6M | |
| Operating Income | (76.2M) | (134.3M) | (167.2M) | (224.3M) | (259.7M) | (246.7M) | |
| Ebit | (76.2M) | (132.7M) | (167.1M) | (220.0M) | (243.7M) | (231.5M) | |
| Research Development | 58.6M | 106.4M | 125.5M | 165.6M | 186.3M | 195.7M | |
| Ebitda | (72.1M) | (131.6M) | (161.7M) | (213.7M) | (236.6M) | (224.8M) | |
| Total Operating Expenses | 75.9M | 134.3M | 166.2M | 223.8M | 259.7M | 272.6M | |
| Income Before Tax | (77.3M) | (139.7M) | (169.1M) | (221.9M) | (245.6M) | (233.3M) | |
| Total Other Income Expense Net | (1.1M) | (5.4M) | (1.8M) | 2.5M | 14.1M | 14.8M | |
| Net Income | (83.2M) | (146.7M) | (169.6M) | (219.4M) | (245.6M) | (233.3M) | |
| Income Tax Expense | 6.0M | 7.0M | 516K | (2.5M) | (245.6M) | (233.3M) | |
| Gross Profit | (426K) | (1.1M) | (5.4M) | (6.3M) | (7.1M) | (6.7M) | |
| Net Income From Continuing Ops | (77.5M) | (139.7M) | (169.1M) | (221.9M) | (252.7M) | (240.0M) | |
| Cost Of Revenue | 426K | 1.1M | 5.4M | 6.3M | 7.1M | 7.5M | |
| Net Income Applicable To Common Shares | (77.3M) | (139.7M) | (169.1M) | (221.9M) | (199.7M) | (189.7M) | |
| Non Operating Income Net Other | 2.5M | 4.6M | 1.6M | 156K | 179.4K | 188.4K | |
| Net Interest Income | (2.5M) | (4.8M) | (2.8M) | 2.0M | 12.3M | 12.9M | |
| Interest Income | 3.4M | 2.2M | 3.1M | 3.9M | 13.1M | 13.7M | |
| Reconciled Depreciation | 426K | 1.1M | 5.4M | 6.3M | 6.9M | 7.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.